Member Info for Cuddles48

Mismis to be honest I am just trying to start a debate to widen the potential investor interest.

But no one seems to be following this one which is a shame as it could be quite a ride.

Mismis
FAB is very very much under the radar not many private investors as most shares held by early investors ans companies linked to the founders and board.

But the potential in a new biotech landscape post Covid is very exciting to those that do their own research as I have. I have spoken with the CEO and I have listened to his presentation to shareholders after last results. I believe he is telling the truth when he states we that he believes the optimal platform when full functional will be a major asset with a billion dollar valuation

But I for one don’t think he will see that realised as I think it is highly likely that a big Pharma company will take them over for a premium cash payment way before that valuation is achieved.

At what price I don’t know but I am guessing it will be way way higher than £1.17 Current selling price.

I am happy to put my money where my big mouth is.

I’m just a tad surprised more haven’t spotted the potential.

But hey ho let’s see shall we.

Well that’s my opinion given the trades and the news expected on the Covid antibody. Or an update on the potential milestone payments they can secure.

129 being paid now this is ready to fly.

MM willing to pay 120 now but won’t raise the screen bid ?

Only 10,000 shares left at 124 then it jumps to 129.

Stick running low

Had to go to fill or kill to buy small amount today first trade free float won’t last long. Should tick up as MM willing to pay 114 already. Tiny amount left at 120 then it should tick up.

Only 10,000 shares on offer at 119 then best is 125

Should be. A bargain for someone

Only 10,000 shares on offer at 119 then best is 125

Should be. A bargain for someone

London you are spot on with the low free float I calculate it must be very close to only 20 to 23%

Hence anyone wanting a few should buy now whilst mM seem happy to make some available.

You won’t get any after any good news at these prices.

https://www-bloomberg-com.cdn.ampproject.org/c/s/www.bloomberg.com/amp/news/articles/2020-12-15/covid-shined-light-on-biotech-and-bulls-see-even-brighter-2021
I particular Like this line.
Biotech bulls are continuing to bet on emerging platforms to treat diseases like cancer.

The 1st is Covid-19 therapeutic antibodies project.

The other 3 are immuno oncology targets.

Should get news on the Covid study in the new year ans the rest later.

Clue from website?

OptiMAL® is currently being used in four exciting proof of concept studies. Contact us for more information and monitor our news section for further updates.

FAB tick all the boxes

https://www.nasdaq.com/articles/thank-you-for-investing-in-science-2020-12-28

Seeing a few decent buys starting to dribble through today. No sells of any note today. Maybe the tide is starting to turn. I am sure there will be news update early in 2021 on Covid antibody progress

Building on strong scientific expertise and application knowhow, Fusion Antibodies and Queen’s University Belfast will be using the Invest Northern Ireland grant to pioneer a new commercially-competitive antibody development platform. The novel technology will be capable of simultaneously creating COVID-19 antibodies of unparalleled quality: humanized, affinity- and selectivity-matured, stability- and developability-optimized. These state-of-the-art antibodies will have a SARS-CoV-2 virus neutralization ability, while also aiding diagnostic testing efforts.

At NICADA, we envisage a breakthrough antibody drug therapy targeting SARS-CoV-2 directly. The Invest Northern Ireland grant will enable us to exploit our SARS-CoV-2 virology expertise to help generate a new antibody development platform that will allow us to realize this vision, helping us to discover new drug targets to combat the devastating COVID-19 disease.”

Ultan Power, Professor of Molecular Virology at The Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast

The COVID-19 pandemic has prompted rising demand for select antibodies, specifically engineered to neutralize the SARS-CoV-2 virus, while also facilitating diagnostic testing. Since the early stages of the pandemic, Fusion Antibodies has been committed to discovering new therapeutic and diagnostic approaches to help in the fight against this growing threat. The new funding is set to further strengthen NICADA, enabling us to provide the global biopharmaceutical and clinical diagnostics communities with the necessary tools they need to mount an effective COVID-19 response."

Dr Paul Kerr, CEO, Fusion Antibodies

Time to buy is before any updates.

Paul Kerr post on Linkedin

As nations try to manage the 3rd wave the solutions Fusion Antibodies can bring fighing this diease is needed. Proud of all our staff and partners and look forward to 2021 with optimism #innovation #antibodies #covid

Worth reading this again from the recent grant award.

The Grant will be used by Fusion to support the Company's mammalian antibody Library research and development programme and will reinforce the work being performed at Fusion to produce fully human antibodies targeting the SARS-CoV-2 virus which could be used in therapeutic and diagnostic applications. This work also forms one part of the strategic multi-target development of the Company's mammalian antibody library. The balance of the GBP453,000 total NICADA grant will be made to QUB to enable their scientists who have access to the SARS-CoV-2 virus to undertake testing and validation of the anti-COVID-19 antibodies and antigens produced and owned by the Company.